Category

Archives

Blog of Signaling Pathways

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

197 views | Apr 27 2022

Kiran Kundu et al. provided a rationale for lurbinectedin in combination with ATR inhibitors to overcome resistance in SCLC with low SLFN11 expression. [Read the Full Post]

Long non-coding RNA ATXN8OS Promotes Ferroptosis and Inhibits the Temozolomide-resistance of Gliomas Through the ADAR/GLS2 Pathway

174 views | Apr 26 2022

Jin Luo et al. found that ATXN8OS mediated ferroptosis and regulated the TMZ-resistance of glioma via ADAR/GLS2 pathway. [Read the Full Post]

Treatment of a Double Cancer Patient With Primary Inferior Vena Cava Sarcoma and Lung Adenocarcinoma: A Case Report and Literature Review

131 views | Apr 26 2022

Xiaohu Guo et al. found that surgery was still an effective treatment for patients with a primary IVC leiomyosarcoma and lung adenocarcinoma at present. [Read the Full Post]

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer

53 views | Apr 25 2022

Dimitrios Korentzelos et al. suggested that IFNγ might be useful in combinatorial regimens to induce sensitivity to immunotherapy and chemotherapy in hepatic metastases of mCRPC. [Read the Full Post]

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

156 views | Apr 25 2022

Tomi Jun et al. thought that everolimus plus paclitaxel demonstrated clinical activity in cisplatin-ineligible patients with metastatic UC, although the specific contribution of everolimus could not be delineated. [Read the Full Post]

Proangiogenesis effects of compound danshen dripping pills in zebrafish

122 views | Apr 24 2022

Yang-Xi Hu et al. found that CDDP had a proangiogenic effect, the mechanism of which involved the VEGF/VEGFR and PI3K/AKT signaling pathways. [Read the Full Post]

Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers

253 views | Apr 24 2022

Fabiana Ciciriello et al. proposed that the functional CFTR assay might guide personalized medicine in patients with CF-like clinical manifestations as well as in those carrying rare CFTR mutations. [Read the Full Post]

Changes in Blood Cell Deformability in Chorea-Acanthocytosis and Effects of Treatment With Dasatinib or Lithium

130 views | Apr 23 2022

Felix Reichel et al. found that the need for a systematic assessment of the contribution of impaired blood cell mechanics to the clinical manifestation of ChAc. [Read the Full Post]

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

252 views | Apr 23 2022

Hidekatsu Nakai et al, found that the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized. [Read the Full Post]

Iguratimod Inhibits Skin Fibrosis by regulating TGF-β1/Smad Signaling Pathway in Systemic Sclerosis

169 views | Apr 22 2022

Xi Xie et al. indicated T614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF-β1/smad pathway in experimental SSc models and might be a promising therapeutic agent for SSc. [Read the Full Post]

First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study

134 views | Apr 22 2022

Yoko Tsukita et al. reviewed data from the randomized clinical trials of first-line EGFR-TKIs including a subset of Japanese patients and discussed first-line therapies for patients with NSCLC harbouring EGFR mutations. [Read the Full Post]

Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma

70 views | Apr 21 2022

Libin Zhou et al.defined a robust signature that might be promising for predicting clinical outcomes and immunotherapy and targeted therapy response in ccRCC patients. [Read the Full Post]

A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment

247 views | Apr 21 2022

Yongluo Jiang et al. developed a CT-based radiomics model to predict subsequent BM in patients with non-brain metastatic NSCLC undergoing crizotinib treatment. [Read the Full Post]

Diet impacts triple-negative breast cancer growth, metastatic potential, chemotherapy responsiveness, and doxorubicin-mediated cardiac dysfunction

157 views | Apr 20 2022

Manuel U Ramirez et al. found that the Mediterranean diet might reduce lung metastatic lesions formation and prevent the development of cardiac toxicities. [Read the Full Post]

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

281 views | Apr 20 2022

Sara Pescatori et al. thought that CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs. [Read the Full Post]

Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer

395 views | Apr 19 2022

Yujun Hao et al. found that the drug combination could be an effective therapeutic approach for PIK3CA helical domain mutant tumors. [Read the Full Post]

Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer

153 views | Apr 19 2022

Xinting Zheng et al. found that the mechanisms of resistance to sotorasib and determine the efficacy and safety of combination therapy for the treatment of NSCLC containing the KRAS G12C mutation. [Read the Full Post]

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

73 views | Apr 18 2022

Tina Ernst et al. described a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib. [Read the Full Post]

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

177 views | Apr 18 2022

Wendao Li et al. found that the JAK inhibitors baricitinib and tofacitinib were promising therapeutic agents for patients with SAVI, AGS, and SPENCD, especially for the improvement of cutaneous lesions and febrile attacks. [Read the Full Post]

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

82 views | Apr 17 2022

Tait D Shanafelt et al. found that Ibrutinib-rituximab therapy offered superior PFS relative to FCR in both IGHV mutated and unmutated CLL patients as well as superior OS. [Read the Full Post]